SILENCE THER. (SLN)

 

SLN Share PerformanceMore

52 week high169.75 18/12/15
52 week low96.65 10/08/16
52 week change -56.25 (-34.09%)
4 week volume301,569 11/11/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

CRISPR/Cas9 Gene Editing Data

RNS Number: 1506P Silence Therapeutics PLC 15 November 2016 CRISPR/Cas9 Gene Editing Data A single-particle RNA based approach to in vivo CRISPR/Cas9 gene editing London, 15 November 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment o...

Broker Forecast - Canaccord Genuity issues a broker note on Silence Therapeutics PLC

Canaccord Genuity today reaffirms its buy investment rating on Silence Therapeutics PLC (LON:SLN) and raised its price...

Silence Therapeutics widens H1 loss

Silence Therapeutics has turned in an H1 pretax loss of 5.5m, from a year-earlier's loss of 4.1m. "Silence has been fully focus...

Half-year Report

RNS Number: 8769K Silence Therapeutics PLC 27 September 2016 27 Sept e mber 2 0 16 I n t e r i m results for the six months ended 30 June 2016 Liver focus, patent portfolio validation and strengthened leadership L o n d o n , 27 S e p t emb e r 2 0 1 6 - Sil e n ce Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and developm...

Notice of Results

RNS Number: 4927K Silence Therapeutics PLC 22 September 2016 22 September 2016 Notice of Results London, 22 September 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results f...

Appointment of CSO and Non-Executive Director

RNS Number: 8797I Silence Therapeutics PLC 05 September 2016 5 September 2016 Silence Therapeutics appoints Dmitry Samarsky, PhD as Chief Scientific Officer and Dr Andy Richards CBE as Non-Executive Director Silence Therapeutics Plc, AIM: SLN, (" Silence " or " the Company ") a leader in the discovery, delivery and development of novel RNA therapeutic...

Director/PDMR Shareholding

RNS Number: 3962E Silence Therapeutics PLC 18 July 2016 Grant of share options to Chief Financial Officer 18 July 2016 Pursuant to the announcement of 24 May 2016, Silence Therapeutics plc ("Silence" or the "Company"), AIM: SLN, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, confirms that D...

Silence resolutions passed at AGM

Silence Therapeutics, a leader in the development and delivery of novel RNA therapeutics, has confirmed that all resolutio...

Fundamental DataMore

EPS-10.4
Dividend yield0 %

Latest discussion posts More

  • interesting article

    http://rnaitherapeutics.blogspot.co.uk/
    7-Jul-2014
    duringthewar
  • Re: shafted again

    o/t Thanks to all those that have supported this campaign ~~~~~ *3,717 voted so far~~~~~(That's a lot of irate investors?) Campaign to make short-selling illegal (or ...
    10-Jun-2014
    dickie3times
  • shafted again

    'I am pleased by the support of key investors at a time of heavy market volatility. I look forward to progressing Silence's pipeline with our expanded resources.' and all ...
    28-Apr-2014
    nick2name

Users' HoldingsMore

Users who hold SILENCE THER. also hold..
LLOYDS GRP.28%
BP26%
ROYAL BANK SCOT20%
BARCLAYS18%
TESCO16%

Codes & Symbols

ISINGB00B9GTXM62
SymbolsSLN, LSE:SLN, SLN.L, SLN:LN, LON:SLN, XLON:SLN